An assessment of the direct and indirect costs of bladder cancer preceding and following a cystectomy: a real-world evidence study by Joseph Tkacz (13138932)

“…Follow up STD claims increased 23.4% equating to a mean 218 ± 324 h lost and $3,679 ± $7,795 per patient. …”

Activation of ICE<i>Bs1</i> that is unable to excise causes DNA damage. by Saria A. McKeithen-Mead (3216084)

Means and variances of the bootstrapped volumes per model type and landmarks added. by Ruth S. Sonnweber (426120)

“…<p>a) The mean volume was affected by the type of model (large, middle, or small) as well as by the percentage of landmarks added. …”

The adenosine A_2A antagonist MSX-3 reverses the effects of TBZ on the PROG/Chow procedure. by Patrick A. Randall (302096)

“…<p>On measures of lever pressing, mean (<u>+</u>SEM) total lever presses (A), highest ratio achieved (B), and active lever time (measured in seconds, C), TBZ produced significant decreases at 0.75 mg/kg. …”

Viability of FTY720-treated T_CM A. by Rachel S. Resop (9238645)

Decreased dendritic arbor length of principal neurons from the basolateral amygdala (BLA) of short-term sucrose consuming rats compared to control rats. by Masroor Shariff (2583442)

“…<p><b>A</b> shows a scatter-plot of decreased total dendritic arbor (mean ± SEM) from the BLA in short-term sucrose rats (open squares) compared to controls (open circles) (Unpaired two-tailed Students <i>t</i>-test,*<i>P</i> < 0.05, <i>n</i> = 7; control and <i>n</i> = 7; 4 week sucrose). …”

Decreased cellular iron uptake attenuates the effector CD8⁺ T cell response to <i>P</i>. <i>chabaudi</i>. by Sarah K. Wideman (17118275)

Decreased cellular iron uptake disrupts the effector CD4⁺ T cell response to <i>P</i>. <i>chabaudi</i>. by Sarah K. Wideman (17118275)

Multivariable-adjusted odds ratio (aOR) for high biomarkers of iron metabolism according to quartile of lung function. by Jonghoo Lee (4831776)

“…<p>The aOR for hyperferritinemia increased with decreasing quartiles of FEV1% and FVC% (A) in a dose-response manner. …”

SDS-PAGE (10%) of culture supernatant of representative HESA-derived Tn5 mutants H28–35 (Table 1) cultured for 16 h. by Marion Schoof (11999106)

Histogram of gastroenteritis in a rural village, Kazakhstan, May–June 2021 (N = 154). by Madina Orysbayeva (14241331)

Fig 2 - by Manel Bouraoui (18707118)

Fig 1 - by Manel Bouraoui (18707118)

Metabolites and gut microbial products. by Ditte Olsen Lützhøft (10837857)

Synergistic Increases in SOD1 Aggregation Propensity and Losses of Thermodynamic Stability Are Associated with Decreased Survival of fALS Patients (Using Unweighted Data) by Qi Wang (22418)

“…<div><p>(A) An increase in aggregation propensity is associated with decreased fALS patient survival. …”

Image_10_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.t... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_1_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_4_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_3_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”

Image_8_In Vitro Characterization of 177Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer.ti... by Tabassom Mohajershojai (9441050)

“…Moreover, the heat shock protein 90 inhibitor onalespib has previously demonstrated radiotherapy potentiation effects in vivo. In the present study, a ¹⁷⁷Lu-radiolabeled anti-CEA hT84.66-M5A mAb (M5A) conjugate was developed and the potential therapeutic effects of ¹⁷⁷Lu-DOTA-M5A and/or onalespib were investigated. …”